Tschochner H J, Bockhorn V, John H, Katenkamp D, Kühnert M, Möller A, Müller H J, Ruffert K, Stadie G, Stiller D
Urologische Klinik Weidenplan, Bezirkskrankenhauses Halle/S.
Z Urol Nephrol. 1987 Oct;80(10):587-93.
The results of the treatment of 194 patients with non-seminomas were analyzed and statistically registered. The therapeutic approach is described and the cumulative probability of survival is compared according to the stages. For the total number of these tumours a cumulative 5-year-survival probability of 68.6% was calculated. In detail it reaches from 100% in clinical stage I to 39.7% in clinical stage III. The decisive change of the prognosis is between the clinical stages IIb and IIc. An adjuvant cytostatic therapy should, if performed, be aggressive. Relapses in the clinical stage I are possible and call for a critical valuation of the primary stage. A retarded cytostatic polychemotherapy should be performed only under certain conditions.
对194例非精原细胞瘤患者的治疗结果进行了分析并进行统计学记录。描述了治疗方法,并根据分期比较了累积生存概率。对于这些肿瘤的总数,计算出累积5年生存概率为68.6%。具体而言,从临床I期的100%到临床III期的39.7%。预后的决定性变化发生在临床IIb期和IIc期之间。如果进行辅助性细胞抑制治疗,应该积极进行。临床I期可能会复发,这需要对原发阶段进行批判性评估。延迟性细胞抑制多药化疗仅在特定条件下进行。